Mona  Ashiya net worth and biography

Mona Ashiya Biography and Net Worth

Director of Disc Medicine

Mona Ashiya is a Partner at OrbiMed Advisors LLC (“OrbiMed”) where she has been involved in a number of private and public company investments.  Prior to joining OrbiMed in 2010, Mona covered the biotechnology industry as a member of J.P. Morgan’s biotechnology equity research team.  Her previous experience includes positions at the Global Alliance for Tuberculosis Drug Development and the Harvard Business School. She earned a B.A. degree from the University of California at Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and was a post-doctoral fellow at the Dana Farber Cancer Institute.

What is Mona Ashiya's net worth?

The estimated net worth of Mona Ashiya is at least $10.65 million as of March 10th, 2025. Ashiya owns 208,742 shares of Disc Medicine stock worth more than $10,650,017 as of March 14th. This net worth evaluation does not reflect any other assets that Ashiya may own. Learn More about Mona Ashiya's net worth.

How do I contact Mona Ashiya?

The corporate mailing address for Ashiya and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at [email protected]. Learn More on Mona Ashiya's contact information.

Has Mona Ashiya been buying or selling shares of Disc Medicine?

Within the last three months, Mona Ashiya has sold $15,503,766.24 of Disc Medicine stock. Most recently, Mona Ashiya sold 83,182 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $54.45, for a transaction totalling $4,529,259.90. Following the completion of the sale, the director now directly owns 194,209 shares of the company's stock, valued at $10,574,680.05. Learn More on Mona Ashiya's trading history.

Who are Disc Medicine's active insiders?

Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.

Are insiders buying or selling shares of Disc Medicine?

During the last year, insiders at the sold shares 19 times. They sold a total of 395,005 shares worth more than $22,156,241.87. The most recent insider tranaction occured on March, 12th when Director Mona Ashiya sold 83,182 shares worth more than $4,529,259.90. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.

Information on this page was last updated on 3/12/2025.

Mona Ashiya Insider Trading History at Disc Medicine

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2025Sell83,182$54.45$4,529,259.90194,209View SEC Filing Icon  
3/10/2025Sell202,146$54.29$10,974,506.34208,742View SEC Filing Icon  
12/18/2023Sell1,724$59.24$102,129.76View SEC Filing Icon  
See Full Table

Mona Ashiya Buying and Selling Activity at Disc Medicine

This chart shows Mona Ashiya's buying and selling at Disc Medicine by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Disc Medicine Company Overview

Disc Medicine logo
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $51.02
Low: $50.74
High: $53.64

50 Day Range

MA: $56.16
Low: $51.02
High: $62.54

2 Week Range

Now: $51.02
Low: $25.60
High: $68.86

Volume

283,282 shs

Average Volume

361,575 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73